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Abstract
Objectives To examine 25 year trends in first time hospitalisation for
acute myocardial infarction in Denmark, subsequent short and long term
mortality, and the prognostic impact of sex and comorbidity.
Design Nationwide population based cohort study using medical
registries.
Setting All hospitals in Denmark.
Subjects 234 331 patients with a first time hospitalisation for myocardial
infarction from 1984 through 2008.
Main outcome measures Standardised incidence rate of myocardial
infarction and 30 day and 31–365 day mortality by sex. Comorbidity
categories were defined as normal, moderate, severe, and very severe
according to the Charlson comorbidity index, and were compared by
means of mortality rate ratios based on Cox regression.
Results The standardised incidence rate per 100 000 people decreased
in the 25 year period by 37% for women (from 209 to 131) and by 48%
for men (from 410 to 213). The 30 day, 31–365 day, and one year
mortality declined from 31.4%, 15.6%, and 42.1% in 1984–8 to 14.8%,
11.1%, and 24.2% in 2004–8, respectively. After adjustment for age at
time of myocardial infarction, men and women had the same one year
risk of dying. The mortality reduction was independent of comorbidity
category. Comparing patients with very severe versus normal comorbidity
during 2004–8, the mortality rate ratio, adjusted for age and sex, was
1.96 (95% CI 1.83 to 2.11) within 30 days and 3.89 (3.58 to 4.24) within
31–365 days.
Conclusions The rate of first time hospitalisation for myocardial infarction
and subsequent short term mortality both declined by nearly half between
1984 and 2008. The reduction in mortality occurred for all patients,
independent of sex and comorbidity. However, comorbidity burden was
a strong prognostic factor for short and long term mortality, while sex
was not.
Introduction
Despite considerable improvements in prophylaxis and
treatment,
1-3 myocardial infarction remains a common life
threatening disease and an enormous burden on Western
healthcare systems.
1 The incidence of and mortality from
myocardial infarction are not continuously monitored by
surveillance registries, despite the critical need for ongoing
evaluation of its primary and tertiary prevention.
As people age, they are more likely to develop chronic medical
conditions. About 45% of the adult population has at least one
chronic disease.
4 This proportion increases to 90% in persons
older than 65 years,
4 who represent more than half of patients
with myocardial infarction.
5 Myocardial infarction shares risk
factors with many chronic diseases (such as obesity, diabetes,
chronicobstructivepulmonarydisease,andcancer
6),increasing
the prevalence of comorbidity among patients with myocardial
infarction.
7 8 Comorbidity potentially modifies effectiveness of
therapies and the clinical course of a myocardial infarction.
8 9
However, clinical guidelines for treatment of myocardial
infarction are based on the results of trials that often exclude
patients of advanced age or with a large number of comorbid
conditions.
10
With the availability of new therapies that also benefit older
patients,
11 it has become increasingly important to understand
the impact of comorbidity on the prognosis of myocardial
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Research
RESEARCHinfarction and to determine whether trends in survival apply to
all patients with myocardial infarction.
12 Previous studies on
this topic have been limited by size (<4100 participants),
9 13
inclusion period (<6 years),
9 13 or selective inclusion of patients
from specific hospitals
9 13 or age groups.
9 Also, the prognostic
impact of sex remains unclear because of conflicting study
findings.
14-17 We therefore conducted a nationwide, population
based,cohortstudytoexaminetrendsinfirsttimehospitalisation
for myocardial infarction over the 25 year period from 1984 to
2008, subsequent short term and long term mortality, and the
prognostic impact of sex and comorbidity.
Methods
Setting
We conducted this cohort study in Denmark, which has 5.4
million inhabitants. The Danish National Health Service
provides universal, tax supported, healthcare, guaranteeing
unfettered access to general practitioners and hospitals and
partial reimbursement for prescribed drugs. Accurate and
unambiguous linkage of all registries at the individual level is
possible in Denmark by means of the unique central personal
registry number assigned to each Danish citizen at birth and to
residents on immigration.
18
Acute myocardial infarction
We used the Danish National Registry of Patients
19 to identify
all first time hospitalisations for myocardial infarction from 1
January 1984 to 31 December 2008 among Danish born
inhabitants aged 15 years or older. This registry contains data
on dates of admission and discharge from all Danish
non-psychiatrichospitalssince1977andfromemergencyroom
andoutpatientclinicvisitssince1995.
19Eachhospitaldischarge
or outpatient visit is recorded in the registry with one primary
diagnosis and one or more secondary diagnoses classified
accordingtoICD-8(internationalclassificationofdiseases,8th
revision) until the end of 1993 and ICD-10 (10th revision)
thereafter.
19 Patients with myocardial infarction are included in
the Danish National Registry of Patients if they died in the
ambulance on the way to the hospital or during the hospital
admission, but not if they died at home. We used ICD-8 codes
410.09 and 410.99 and ICD-10 code I21 to identify myocardial
infarction.
Mortality
We obtained information on all cause mortality until the end of
2009 from the Danish Civil Registration System.
18 20 This
registry has recorded all changes in vital status and migration
fortheentireDanishpopulationsince1968,withdailyelectronic
updates.
18
Comorbidity
Weobtainedinformationoncomorbidconditionsfrominpatient
and outpatient hospital diagnoses (all available primary or
secondary diagnoses) recorded in the Danish National Registry
of Patients in the five years before the myocardial infarction.
To avoid inclusion of complications caused by the myocardial
infarction,secondarydiagnosescodedduringtheadmissionfor
myocardial infarction were excluded. We categorised the
severityofcomorbidityusingtheCharlsoncomorbidityindex,
21
a scoring system that has been adapted for use with hospital
dischargedata
9andvalidatedforpatientswithacuteandchronic
ischaemic heart disease.
8 9 22 23 The index assigns between one
and six points to a range of diseases, depending on the strength
of their relation to mortality in the subsequent year (during the
era when the Charlson comorbidity index was developed): one
point for myocardial infarction, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, connective tissue disease, ulcer
disease, mild liver disease, and diabetes without end organ
damage; two points for diabetes with end organ damage,
hemiplegia, moderate to severe renal disease, non-metastatic
solid tumour, leukaemia, and lymphoma; three points for
moderatetosevereliverdisease;sixpointsformetastaticcancer
and AIDS. We computed the total Charlson score for each
patient and defined four categories of comorbidity as used in
the Predicting Risk of Death in Cardiac Disease Tool
(PREDICT) study—that is, total scores of 0 (normal), 1
(moderate), 2 (severe), and ≥3 (very severe).
22 Myocardial
infarction was not included in the scoring. The Charlson
comorbidity index and associated ICD codes are provided in
web extra table A on bmj.com.
Statistical analysis
We computed and illustrated graphically the incidence rate of
myocardial infarction (standardised to the age distribution of
the Danish population in the year 2000) and subsequent 30 day
and 31–365 day mortality (standardised to the age distribution
of the population diagnosed with myocardial infarction in the
year 2000) for men and women from 1984 through 2008.
23 We
calculatedconfidenceintervalsusingtheapproximatebootstrap
method.
24 25 We repeated the analyses for subgroups of patients
aged 35–49, 50–59, 60–69, 70–79, and ≥80 years.
We then characterised patients with myocardial infarction
according to sex, age, and comorbidity category, overall and
for five calendar periods of diagnosis (1984–8, 1989–93,
1994–8,1999–2003,and2004–8).Wecalculatedtheprevalence
ofindividualCharlsoncomorbiditiesregisteredinthefiveyears
precedingtheadmissionformyocardialinfarction.Weillustrated
graphically the change in median age from 1984 through 2008
for both men and women.
We followed all patients until the date of death, emigration, or
one year of follow-up, whichever came first. Using the
Kaplan-Meierestimator,
25wecomputedthe30dayand31–365
day mortality risk associated with each calendar period of
diagnosisandcomorbiditycategory.WeusedCoxproportional
hazards regression to estimate the mortality rate ratio
(specifically, the hazard ratio) associated with calendar period
of diagnosis and comorbidity category within 30 days and
31–365 days after myocardial infarction.
First,wecomparedmortalityratesacrosscalendarperiods,using
the earliest period as the reference and adjusting for sex, age
groups, and comorbidity categories. To evaluate the potential
for residual confounding by age and comorbidity, we repeated
theanalysismodellingageandcomorbiditybythreeknotcubic
splines.
25 The results were consistent with the categorical
modelling strategy and are therefore not reported further.
Second, we compared mortality rates across comorbidity
categories, using normal comorbidity category as the reference
and adjusting for sex and age groups. Within the 2004–8
calendar period of diagnosis, we also examined the 30 day and
31–365 day mortality rate ratios associated with the individual
Charlson comorbidities, adjusting for the other comorbidities,
age,andsex.Theproportionalhazardsassumptionwasassessed
graphicallybyplottinglog(−log(survivalfunction))againsttime
for all exposure variables and found to be valid.
25
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RESEARCHResults
Incidence
Weidentified234 331firsttimehospitalisationsformyocardial
infarction in Denmark from 1984 through 2008. The Danish
populationinthis25yearperiodconsistedof5 610 039Danish
borninhabitantsaged15yearsorolder.Theannualstandardised
incidence rate of myocardial infarction (per 100 000 people)
decreased during this period, by 37% for women (from 209 to
131)andby48%formen(from410to213)(fig1⇓).Atransient
increase in incidence occurred between 2000 and 2004 (fig 1).
It was driven by the incidence among people aged ≥70 years,
particularlythoseaged≥80years(fig2⇓).Forpatientsyounger
than 70 years, the incidence steadily decreased throughout the
25 year period (fig 2).
Patient characteristics
Although the female proportion of patients with myocardial
infarctionincreasedslightlybetweenthefirstfiveyearcalendar
period(35.8%)andthelast(38.8%),menstillaccountedforthe
majority(62.1%)ofallhospitalisationsformyocardialinfarction
(table 1⇓). The median age at time of diagnosis was 75 years
for women and 68 for men. While the median age held fairly
steady at about 68 years for men, it increased for women from
74 years in 1984 to 77 years in 2008 (web extra fig A on
bmj.com). The prevalence of patients with normal comorbidity
burdenfellfrom75.5%to63.8%betweentheearliestandlatest
calendar period (table 1⇓). The percentage of patients with
moderate comorbidity increased from 13.2% to 16.2%, the
percentage with severe comorbidity increased from 7.4% to
10.5%, and the percentage with very severe comorbidity
increasedfrom3.9%to9.6%(theprevalenceforCharlsonscores
1 to 10 is provided in web extra table B). The most prevalent
Charlson comorbidities were diabetes (7.0%), stroke (7.0%),
congestive heart failure (5.8%), chronic pulmonary disease
(5.8%),peripheralvasculardisease(5.3%),cancer(5.4%),ulcer
disease (2.5%), connective tissue disease (2.1%), and severe
renal disease (1.6%).
Mortality
The standardised 30 day and 31–365 day mortality risks after
first time myocardial infarction were similar for men and
women, decreasing comparably between 1984 and 2008 (fig
3⇓).The30daymortalitydeclinedfrom31.4%(95%confidence
interval: 31.0% to 31.8%) during 1984–8 to 14.8% (14.5% to
15.2%) during 2004–8 (table 2⇓). The one year mortality
declined overall from 42.1% (41.7% to 42.5%) during 1984–8
to 24.2% (23.8% to 24.7%) during 2004–8; and among 30 day
survivors it fell from 15.6% (15.2% to 16.0%) during 1984–8
to11.1%(10.7%to11.4%)during2004–8.Whenthelatestfive
year period was compared with the earliest, the mortality rate
ratio adjusted for age and comorbidity category was 0.37 (95%
confidence interval 0.35 to 0.38) within 30 days and 0.48 (0.47
to 0.51) within 31–365 days. Age stratified analyses revealed
no difference in mortality among men and women within age
categories (web extra fig B on bmj.com).
Prognostic impact of comorbidity
The improvement in mortality after myocardial infarction
between 1984 and 2008 was observed for all patients in all age
groups,independentoftheircomorbiditycategory(fig4⇓).The
30dayand31–365daymortalityriskswerestronglyassociated
with the patient’s category of comorbidity for all five year
calendar periods (web extra table C on bmj.com). With normal
comorbidity category as the reference, the mortality rate ratios
adjusted for age and sex among patients with moderate
comorbidityin2004–8were1.35(95%confidenceinterval1.26
to 1.45) within 30 days and 1.83 (1.68 to 2.00) within 31–365
days(table3⇓).Comparingpatientswithverysevereandnormal
comorbidity in 2004–8, the adjusted mortality rate ratios were
1.96(1.83to2.11)within30daysand3.89(3.58to4.24)within
31–365 days (table 3⇓). The magnitude of the increased
mortality rate ratios associated with increasing comorbidity
categories was similar across calendar periods (web extra table
C).Consistentwiththeprinciplethateffectestimatesarehigher
among those at lower baseline risk, we found that age modified
the mortality rate ratio associated with each comorbidity
category, with higher estimates in younger age groups (web
extra table D).
Amongtheindividualnon-malignantcomorbidities,liverdisease
and dementia were each associated with a roughly doubled
mortality rate within 30 days after myocardial infarction
compared with patients without comorbidity (table 4⇓). Within
31–365 days, twofold increased mortality rate ratios were also
observed for patients with moderate to severe liver or renal
diseases.Congestiveheartfailure,peripheralorcerebrovascular
vascular disease, chronic pulmonary disease, and ulcer disease
were associated with a 1.2 to 1.3-fold increased mortality rate
ratiowithin30days,increasingto1.5-foldwithin31–365days.
Diabetes with end organ damage was associated with 1.3-fold
increasedshorttermandlongtermmortalityrateratios,whereas
connective tissue disease was not.
Discussion
In this nationwide cohort study, we found an almost 50%
reduction both in the first time hospitalisation for myocardial
infarctionbetween1984and2008andinsubsequentshortterm
mortality. During the same period, one year mortality among
30 day survivors declined by a third. The improved survival
since 1984 applied to all myocardial infarction patients
independently of sex and comorbidity. However, the
comorbidity burden measured five years before admission was
a strong predictor of mortality within 30 days after myocardial
infarction and during the remainder of the first year, whereas
sex was not.
Strengths and limitations of study
Several issues should be considered in interpreting our results.
The population based design in a country with universal
healthcare reduced selection biases stemming from selective
inclusion of specific hospitals, health insurance systems, or age
groups. All patients were followed until death, emigration, or
endoffollow-up,andhencenoonehadincompleteregistration.
The positive predictive values of diagnoses in the Danish
National Registry of Patients have previously been validated
and found to exceed 90% for both myocardial infarction
(>90%)
26 and the Charlson comorbidities (98% overall).
27 A
potential limitation was that patients with sudden cardiac death
outside hospital or ambulance or who did not receive a
resuscitationattemptattheemergencyroomwerenotregistered
in the Danish National Registry of Patients. To address this
limitation, we compared over time the proportion of patients
who had myocardial infarctions recorded as cause of death in
the Danish Register of Causes of Death without having it or a
previousmyocardialinfarctionrecordedintheDanishNational
Registry of Patients. This supplementary analysis revealed that
such patients could not account for the observed incidence and
mortality trends.
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RESEARCHOther diseases such as diabetes and chronic pulmonary disease
are likely to be under-represented in the Danish National
RegistryofPatients,becausesomepatientsaretreatedinprimary
care only. Although the 7% prevalence of diabetes among
patients with myocardial infarction is substantially lower than
in other Western countries,
2 it is only slightly lower than
reported in the second Danish trial on Acute Myocardial
Infarction(DANAMI-2)(11%).
28Also,becausethecomparisons
were made within a population of patients with myocardial
infarction, underascertainment of comorbidities is unlikely to
influencesubstantiallytherelativemortalityestimatesassociated
withcomorbiditycategories.ThemortalitydatafromtheDanish
Civil Registration System are virtually complete.
18
As suggested for stable angina pectoris patients,
23 the Charlson
comorbidity index could potentially be made even more
appropriateforpatientswithmyocardialinfarctionbyassigning
greaterweighttosomediseases(suchasliverandrenaldisease)
and omitting others lacking prognostic significance among
patients with myocardial infarction (such as connective tissue
disease)orwithlowprevalence(suchashemiplegia,leukaemia,
and AIDS).
23 29 Also, peripheral and cerebrovascular disease
may to some extent represent “disease staging” of underlying
atherosclerosisthathasprogressedtomultiplevascularsystems,
rather than representing separate disease entities.
29 However,
despitetheselimitationsregardingindividualcomorbidities,the
Charlson comorbidity index in its original form has proved an
adequate tool for measuring the prognostic impact of total
comorbidity burden in patients with myocardial infarction.
9 30
Comparison with other studies
Our study is the first to examine nationwide 25 year trends in
myocardial infarction epidemiology. Its results are in line with
previous US,
31-41 UK,
42 43 Australian,
44 and multinational
3 45
studies examining trends in the incidence and outcomes of
myocardial infarction. Compared with our study, these studies
were conducted over shorter time periods,
34-45 with data
collection before the definition of myocardial infarction was
amended in 2000,
32-34 38 42 45 or in modest sized cohorts such as
the Atherosclerosis Risk in Communities Study,
35 Framingham
Heart Study,
32 33 Minnesota Heart Survey,
34 Perth MONICA
(Monitoring Trends and Determinants in Cardiovascular
Disease) cohort,
44 or Worcester Heart Attack Study.
31 39
It is estimated that half of the decline in mortality since 1980
is attributable to primary prevention of myocardial
infarction—that is, reduction in the prevalence of major
cardiovascularriskfactorssuchassmoking,sedentarylifestyle,
and uncontrolled high blood pressure.
1 2 The other half is
attributabletotheintroductionofthrombolysis,coronaryartery
bypass grafting, percutaneous coronary intervention, and
improvedtertiarymedicalpreventionwithantiplateletregimens,
β blockers, angiotensin converting enzyme inhibitors, and
statins.
1 3 It is noteworthy that the incidence of myocardial
infarctionhascontinuedtodeclinedespiteincreasedprevalence
of obesity and diabetes.
1 2 The transient increase in incidence
between 2000 and 2004 with local maximum in 2002 was
presumablyattributabletonewdiagnosticcriteriathatincluded
troponin as the main diagnostic biomarker of myocardial
infarction.
46 Although we did not discriminate between ST
segment and non-ST segment elevation myocardial infarction,
the changing biomarker use is likely to have increased the
detection rate of smaller infarcts and thus predominantly the
rates of non-ST segment elevation myocardial infarction.
35 36
We observed a larger decrease in myocardial infarction
incidence among men than women until 1997, after which the
decreasing trend seemed independent of sex. One explanation
for this difference is that cardiovascular disease previously was
considered primarily a man’s disease, and thus cardiovascular
diseasepreventionprimarilyfocusedonriskmodificationamong
men. Also, within the last two to three decades, the lifestyles
and risk behaviours of women and men became more similar
with regard to smoking, sedentary work, and working outside
the home. We observed that sex did not influence the prognosis
of myocardial infarction as previously suggested.
14 15 Thus, age
is the single most important prognostic factor to control for
whencomparingmortalityfrommyocardialinfarctionbetween
men and women.
16 17 47
Our study is also the first to examine the short and long term
mortality risks and rates associated with comorbidity burden in
a nationwide population. We observed increased levels of
comorbidity over time. This trend may, however, be explained
partly by the increase in age at time of diagnosis, a more
completediseaseregistration(owingtotheadditionofoutpatient
clinic diagnoses in the Danish National Registry of Patients)
from1995onwards,andtheintroductionofthediagnosisrelated
group system as a prospective payment system around 2000.
Because short term mortality is likely to be closely related to
the severity and progression of myocardial infarction, it is
notable that comorbidity had a substantial influence on 30 day
mortality. Also important, we found that improvements in
survival among patients with myocardial infarction occurred
independentlyoftheircomorbidityburden.Incontrast,survival
improvements for other major diseases, such as breast cancer,
dependonpatients’comorbiditycategories,withpoorersurvival
improvement among those with severe comorbidity.
12
Our large study, including nearly 250 000 patients, extends the
results of two smaller studies that also examined the prognostic
impact of comorbidity burden as classified by the Charlson
comorbidity index.
9 13 O’Connell et al based their analysis on
theMONICAstudyof4081peopleaged25–69yearswhowere
admitted for myocardial infarction between 1988 and 1994 and
who survived for at least 28 days.
9 Their reported association
between comorbidity and mortality (adjusted hazard ratio 1.36
(95% confidence interval 1.07 to 1.72) for moderate to severe
comorbidityand2.74(1.73to4.34)forveryseverecomorbidity)
was consistent with our results. Núñez et al examined the
association between comorbidity and mortality among 1035
patientsadmittedtohospitalwithmyocardialinfarctionbetween
2000 and 2003.
13 The 30 day and one year mortality rate ratios
that they reported were consistent with our results for the
calendar period 1999–2003.
Comorbidity may influence the prognosis of myocardial
infarction in several ways. Comorbid conditions may directly
alter the effectiveness of treatments and affect the course of
myocardial infarction. Although comorbidities are likely to
increasenon-cardiacmortalityinparticular,
48theincreasedshort
term mortality also suggests an impact on cardiac mortality.
Underuse of coronary reperfusion therapy among patients with
comorbid diseases may account for some of the increased
mortality associated with comorbidity within the first 30 days
after hospitalisation for myocardial infarction.
7
Generalisability, implications, and
conclusions
The observed trend for incidence and mortality of myocardial
infarction are likely generalisable to most industrial Western
societies where changes in lifestyle, risk factor modification,
and increasing use of aggressive medical and interventional
treatment have followed international recommendations.
2
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RESEARCHFurthermore, the ratio of mortality rates associated with
comorbidity categories should be unbiased because the
comparisons over time were made between patients all with
myocardial infarction.
25
Our findings have implications for research and clinical care.
Clinical trials should include patients with prevalent comorbid
illnesssothatresultsmaybeextrapolatedtotheentirespectrum
of patients with myocardial infarction.
5 Cardiovascular disease
registriesshouldmeasurecomorbiditiestopermitfairinferences
regarding mortality, process of care, and risk stratification after
myocardial infarction.
8 22 Finally, comorbidity should be
considered in individual patient counselling, with treatment
optimised to improve the outcome both of the comorbid
condition and the myocardial infarction. Our findings are
particularly important for elderly people, given their high
prevalenceofcomorbidity
4andtheincreasingnumbersofpeople
of advanced age facing treatment decisions for coronary artery
disease.
4 5
Inconclusion,wefoundthattherateoffirsttimehospitalisation
for myocardial infarction and subsequent short term mortality
both declined by nearly half between 1984 and 2008. The
reduction in mortality occurred for all patients, independent of
sex and the severity of comorbidity. However, comorbidity
burden was a strong prognostic factor for short and long term
mortality, while sex was not.
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RESEARCHTables
Table 1| Numbers (percentages) of people with a first time hospitalisation for myocardial infarction in Denmark in five year periods from
1984 through 2008 by sex, age, and comorbidity category
Total (n=234 331)
Calendar periods of diagnosis
2004–8 (n=41 002) 1999–2003 (n=44 365) 1994–8 (n=42 261) 1989–93 (n=50 249) 1984–8 (n=56 454)
Sex:
88 708 (37.9) 15 926 (38.8) 17 652 (39.8) 16 238 (38.4) 18 691 (37.2) 20 201 (35.8) Female
145 623 (62.1) 25 076 (61.2) 26 713 (60.2) 26 023 (61.6) 31 558 (62.8) 36 253 (64.2) Male
Age (years):
1 077 (0.5) 224 (0.5) 228 (0.5) 223 (0.5) 196 (0.4) 206 (0.4) 15–34
16 697 (7.1) 3 185 (7.8) 3 172 (7.1) 2 974 (7.0) 3 521 (7.0) 3 845 (6.8) 35–49
34 906 (14.9) 6 296 (15.4) 6 859 (15.5) 6 176 (14.6) 7 241 (14.4) 8 334 (14.8) 50–59
57 439 (24.5) 9 227 (22.5) 9 604 (21.6) 10 020 (23.7) 12 978 (25.8) 15 610 (27.7) 60–69
70 997 (30.3) 10 526 (25.7) 12 617 (28.4) 13 309 (31.5) 16 080 (32.0) 18 465 (32.7) 70–79
53 215 (22.7) 11 544 (28.2) 11 885 (26.8) 9 559 (22.6) 10 233 (20.4) 9 994 (17.7) ≥80
Comorbidity category*:
164 937 (70.4) 26 157 (63.8) 28 323 (63.8) 30 041 (71.1) 37 771 (75.2) 42 645 (75.5) Normal
34 941 (14.9) 6 633 (16.2) 7 599 (17.1) 6 409 (15.2) 6 845 (13.6) 7 455 (13.2) Moderate
20 327 (8.7) 4 295 (10.5) 4 592 (10.4) 3 571 (8.4) 3 701 (7.4) 4 168 (7.4) Severe
14 126 (6.0) 3 917 (9.6) 3 851 (8.7) 2 240 (5.3) 1 932 (3.8) 2 186 (3.9) Very severe
*Categories of comorbidity were based on Charlson comorbidity index scores of 0 (normal), 1 (moderate), 2 (severe), and ≥3 (very severe).
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RESEARCHTable 2| 30 day and 31–365 day mortality risk and mortality rate ratio after first time hospitalisation for myocardial infarction in Denmark
in five year periods of diagnosis from 1984 through 2008
31–365 day mortality 30 day mortality
Median
age
(years)
No of
patients
Period of
diagnosis
Mortality rate ratio (95% CI)
Mortality risk %
(95% CI)
Mortality rate ratio (95% CI)
Mortality risk %
(95% CI) Adjusted* Unadjusted Adjusted* Unadjusted
1 (reference) 1 (reference) 15.6 (15.2 to 16.0) 1 (reference) 1 (reference) 31.4 (31.0 to 31.8) 70 56 454 1984–8
0.79 (0.76 to 0.82) 0.83 (0.80 to 0.87) 13.2 (12.9 to 13.6) 0.84 (0.82 to 0.86) 0.86 (0.84 to 0.88) 27.4 (27.1 to 27.8) 70 50 249 1989–93
0.63 (0.60 to 0.66) 0.73 (0.70 to 0.76) 11.7 (11.3 to 12.0) 0.68 (0.67 to 0.70) 0.73 (0.71 to 0.75) 23.8 (23.4 to 24.2) 71 42 261 1994–8
0.56 (0.54 to 0.58) 0.76 (0.73 to 0.79) 12.2 (11.8 to 12.5) 0.46 (0.45 to 0.47) 0.54 (0.52 to 0.55) 18.1 (17.8 to 18.5) 72 44 365 1999–2003
0.48 (0.47 to 0.51) 0.69 (0.66 to 0.72) 11.1 (10.7 to 11.4) 0.37 (0.35 to 0.38) 0.43 (0.42 to 0.44) 14.8 (14.5 to 15.2) 71 41 002 2004–8
*Adjusted for age, sex, and comorbidity category.
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RESEARCHTable 3| 30 day and 31–365 day mortality risk and mortality rate ratio after first time hospitalisation for myocardial infarction in Denmark
between 2004 and 2008 associated with comorbidity category
31–365 day mortality 30 day mortality
No of
patients
Comorbidity
category*
Mortality rate ratio (95% CI)
Mortality risk %
(95% CI)
Mortality rate ratio (95% CI)
Mortality risk %
(95% CI) Adjusted† Unadjusted Adjusted† Unadjusted
1 (reference) 1 (reference) 6.2 (5.9 to 6.5) 1 (reference) 1 (reference) 10.8 (10.4 to 11.2) 26 157 Normal
1.83 (1.68 to 2.00) 2.64 (2.42 to 2.87) 15.5 (14.6 to 16.5) 1.35 (1.26 to 1.45) 1.85 (1.73 to 1.98) 19.2 (18.3 to 20.2) 6633 Moderate
2.50 (2.29 to 2.74) 3.61 (3.30 to 3.96) 20.6 (19.3 to 22.1) 1.52 (1.41 to 1.64) 2.09 (1.94 to 2.25) 21.4 (20.2 to 22.7) 4295 Severe
3.89 (3.58 to 4.24) 5.80 (5.34 to 6.31) 31.2 (29.5 to 32.9) 1.96 (1.83 to 2.11) 2.72 (2.53 to 2.91) 27.1 (25.7 to 28.5) 3917 Very severe
* Categories of comorbidity were based on Charlson comorbidity index scores of 0 (normal), 1 (moderate), 2 (severe), and ≥3 (very severe).
†Adjusted for sex and age.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e356 doi: 10.1136/bmj.e356 (Published 25 January 2012) Page 9 of 12
RESEARCHTable 4| 30 day and 31–365 day mortality rate ratios associated with individual comorbidities after first time hospitalisation for myocardial
infarction in Denmark between 2004 and 2008
Adjusted mortality rate ratio (95% CI)*
31-365 days 30 day
1 (reference) 1 (reference) No comorbid diseases
1.62 (1.48 to 1.78) 1.30 (1.20 to 1.41) Congestive heart failure
1.47 (1.33 to 1.62) 1.23 (1.13 to 1.34) Peripheral vascular disease
1.52 (1.39 to 1.65) 1.21 (1.12 to 1.30) Cerebrovascular disease
1.52 (1.28 to 1.81) 1.81 (1.60 to 2.05) Dementia
1.54 (1.41 to 1.68) 1.21 (1.12 to 1.31) Chronic pulmonary disease
1.05 (0.89 to 1.23) 0.95 (0.82 to 1.09) Connective tissue disease
1.50 (1.31 to 1.72) 1.24 (1.10 to 1.39) Ulcer disease
1.80 (1.22 to 2.67) 2.00 (1.48 to 2.71) Mild liver disease
1.19 (1.05 to 1.34) 0.99 (0.89 to 1.09) Diabetes without end organ damage
1.25 (1.09 to 1.44) 1.30 (1.16 to 1.46) Diabetes with end organ damage
1.68 (0.97 to 2.89) 1.32 (0.79 to 2.19) Hemiplegia
2.08 (1.83 to 2.36) 1.26 (1.11 to 1.42) Moderate to severe renal disease
1.69 (1.53 to 1.87) 1.22 (1.12 to 1.34) Non-metastatic solid tumour
1.89 (1.21 to 2.95) 1.85 (1.32 to 2.59) Leukaemia
1.60 (1.15 to 2.22) 1.40 (1.07 to 1.83) Lymphoma
1.97 (0.94 to 4.10) 2.21 (1.34 to 3.64) Moderate to severe liver disease
2.91 (2.33 to 3.63) 1.58 (1.25 to 2.01) Metastatic cancer
AIDS was omitted from the table because of its low prevalence (<0.1%).
*Adjusted for the other comorbidities, age, and sex.
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RESEARCHFigures
Fig 1 Standardised incidence rates for first time hospitalisation for myocardial infarction in Denmark between 1984 and
2008 among men and women
Fig 2 Standardised incidence rates for first time hospitalisation for myocardial infarction between 1984 and 2008, for men
and women within age groups
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RESEARCHFig 3 Standardised 30 day and 31–365 day mortality after first time hospitalisation for myocardial infarction among men
and women between 1984 and 2008.
Fig 4 30 day and 31–365 day mortality after first time hospitalisation for myocardial infarction between 1984 and 2008,
according to comorbidity category.
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